End-of-day quote
Taipei Exchange
06:00:00 2024-04-29 pm EDT
5-day change
1st Jan Change
93.7
TWD
-1.68%
+6.48%
-11.18%
PharmaEngine : to attend 1H22 financial status investor conference hosted by Cathay Securities
July 26, 2022 at 05:19 am EDT
Provided by: PharmaEngine, Inc.
SEQ_NO
4
Date of announcement
2022/07/26
Time of announcement
17:09:40
Subject
PharmaEngine Inc. to attend 1H22 financial
status investor conference hosted by Cathay Securities
Date of events
2022/07/27
To which item it meets
paragraph 12
Statement
1.Date of institutional investor conference:2022/07/27
2.Time of institutional investor conference:14:00
3.Location of institutional investor conference:Live streaming
4.Outline of institutional investor conference:
Announcement of 1H22 financial status and the FY22 outlook.
5.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
PharmaEngine Inc. published this content on 26 July 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 26 July 2022 09:18:05 UTC .
PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors
Apr. 24
CI
PharmaEngine, Inc. Announces ONIVYDE Obtains TFDA Approval for New Regimen in First-Line Treatment of Metastatic PDAC
Mar. 18
CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 12
CI
PharmaEngine, Inc. Announces Consolidated Revenue Results for the Month and Year Ended December 2023
Feb. 29
CI
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 06
CI
TFDA Approves PharmaEngine, Inc.'s PEP07 Phase I Clinical Trial for Solid Tumor Cancers
23-09-22
CI
PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of Pep07 for Hematological Cancers
23-08-15
CI
PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-04
CI
PharmaEngine, Inc. Announces Dividend, Payable on September 1, 2023
23-07-27
CI
PharmaEngine, Inc. Announces EMAs Acceptance of Onivyde's Type II Variation Application
23-07-11
CI
PharmaEngine, Inc. Files Post-Approval Change Application for A New Indication of ONIVYDE to TFDA
23-06-21
CI
PharmaEngine, Inc. Announces Approval of Phase 1 Clinical Study of Pep07 by TFDA
23-06-14
CI
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-04
CI
PharmaEngine, Inc. Announces Resignation of Peter Wu as Senior Director of Marketing & Sales
23-04-27
CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-17
CI
Australia HREC Approves and Australia TGA Acknowledges PharmaEngine, Inc.'s Phase 1 Clinical Study of PEP07
23-03-03
CI
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-04
CI
PharmaEngine, Inc. Announces Change of Board of Directors Chairperson
22-09-01
CI
PharmaEngine, Inc. Announces Management Changes, Effective September 1, 2022
22-08-30
CI
PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
22-08-03
CI
Pharmaengine, Inc. Announces Dividend for 2021,Payment Date of Cash Dividend Distribution Is September 2, 2022
22-07-26
CI
Pharmaengine, Inc. Approves the Change of the Member of Compensation Committee
22-05-27
CI
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-06
CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-18
CI
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
21-11-09
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,
More about the company
1st Jan change
Capi.
-11.18% 413M +0.67% 42.19B +44.30% 40.15B -6.20% 28.31B +6.55% 24.63B -21.66% 18.2B +29.96% 12.01B -1.57% 11.76B +16.03% 10.4B -4.80% 9.94B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1